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The cellular localization in the liver of the receptor-dependent and -independent uptake of human low 
density lipoprotein (LDL) in normal and 17a-ethinyl estradiol-treated rats was investigated by the 
simultaneous in vivo injection of human 1311-LDL and human reductive methylated “‘1-LDL. The cells 
were subsequently isolated by a low temperature method. In untreated rats, after 30 min of in vivo 
circulation of human LDL, 57% of the receptor-dependent liver-association of human LDL occurs in non- 
parenchymal cells and 43% in parenchymal cells. Estradiol treatment of rats for 3 days selectively increases 
the receptor-dependent cell-association of human LDL with hepatocytes (17-fold), while the receptor- 
dependent cell-association with non-parenchymal cells is not affected. 
Ethinyl estradiol Low density lipoprotein Non-parenchymal liver cell 
Parenchymal iver cell Reductive methylated LDL 
1. INTRODUCTION 
Administration of 17cu-ethinyl estradiol in phar- 
macological amounts to rats produces a profound 
hypolipidemia [l]. The hepatic uptake and 
catabolism of both rat and human low density 
lipoprotein is stimulated many-fold in these rats 
[2]. This enhanced uptake is associated with an in- 
creased number of high affinity binding sites on 
membranes derived from the whole liver [3]. The 
binding site involved is described to be a functional 
lipoprotein receptor that recognizes lipoproteins, 
containing apoprotein B or E [4]. From auto- 
radiographic studies it was concluded that 
estrogen-treatment enhances the normal mec- 
hanism by which LDL is taken up by the liver and 
that both in control and estrogen-treated rats the 
parenchymal cell is the predominant cell type for 
LDL interaction [5]. 
Abbreviations: LDL, low density lipoprotein; Me-LDL, 
reductive methylated LDL 
Here, we have applied a low-temperature cell 
isolation method to determine the tissue site of the 
estradiol-stimulated lipoprotein receptor in the rat 
liver. A discrimination between receptor- 
dependent and -independent association was made 
by the simultaneous injection of native human i311- 
LDL and human reductive methylated “‘1-LDL 
(Me-12?-LDL). As reductive methylation of at 
least 30% of the lysyl residues blocks 
receptor-lipoprotein interaction [6], the difference 
between the amount of cell-association of native 
and Me-LDL can be defined as receptor-mediated 
cell-association or uptake. 
2. MATERIALS AND METHODS 
17cu-Ethinyl estradiol was obtained from 
Brocacef BV (Maarssen); collagenase (type I) from 
Sigma (St Louis MO); pronase B-grade from 
CalBiochem Behring Corp. (La Jolla CA); sodium 
[1251]- and (‘311]iodide (carrier-free) was purchased 
from the Radiochemical Centre (Amersham). 
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lZWeek-old male Wistar rats (250 g av. body 
wt) which had free access to water and food (stan- 
dard laboratory chow), were used. Rats were in- 
jected subcutaneously with 17cu-ethinyl estradiol 
dissolved in propylene glycol at 5 mg/kg body wt 
[2] every 24 h for 3 days. At this time the maximal 
decrease in plasma cholesterol concentration [3,7] 
and increase in LDL receptor-activity [3] is attain- 
ed. Control rats received equal volumes of the 
solvent. 
2.1. Preparation of lipoproteins 
Human LDL (1.024 < d < 1.055 g/ml) was 
isolated as in [8], the isolated LDL was subjected 
to a second identical centrifugation to avoid any 
contamination with other lipoproteins. Apo E con- 
tent of this LDL fraction was < 0.03% of the total 
apoprotein [9]. Radioiodination of LDL was done 
by a modification [lo] of the ICI method in [l 11. 
Reductive methylation of LDL was done as in [6]. 
About 80% of the lysyl residues from human LDL 
were methylated as determined by using the 
2,4,6_trinitrobenzene sulfonic acid calorimetric 
assay [12]. Human 1311-LDL and human Me-“‘I- 
LDL were always prepared from the same LDL- 
preparation, specific radioactivity of both prepara- 
tions varied from 100-500 cpm/ng apoprotein. 
2.2. Fate of LDL in rat serum and liver 
Rats were anesthesized by intraperitoneal injec- 
tion of 20 mg nembutal. The abdomen was opened 
and about 4Opg human 13rI-LDL and 4Opg 
human Me-12’I-LDL in a measured volume (usual- 
ly 500 ~1) of 0.15 M NaCl, 0.3 mM EDTA (pH 
7.0) was injected in the inferior vena cava at the 
level of the renal veins. After 3, 8, 15 and 25 min 
0.2 ml blood was taken from the inferior vena cava 
at least 2 cm distal of the injection point. “‘1 and 
r311 were determined in the serum and the results 
expressed as percentage of the “‘1 or 1311 in the 
sample taken 3 min after the injection. In some ex- 
periments 500 ,ul 12% trichloroacetic acid was add- 
ed to 100 ~1 serum samples to determine the serum 
acid-soluble and acid-precipitable radioactivity. 
After 30 min circulation of the radiolabeled 
lipoproteins the vena porta was carmulated and the 
liver was preperfused with an oxygenated Hanks 
buffer at 8°C. After 8 min perfusion a lobule was 
tied off for determination of the total liver uptake. 
Subsequently, the liver was subjected to a low 
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temperature (8°C) perfusion with 0.25% pronase 
for the isolation of nonparenchymal cells or a low 
temperature (8°C) collagenase (O.OS’J7o) perfusion 
for the isolation of parenchymal cells based upon 
[ 131 and extensively described in [28]. The paren- 
chymal cells were completely free from non- 
parenchymal cells as checked microscopically. The 
non-parenchymal cell preparation was completely 
free from parenchymal cells as checked 
microscopically and biochemically by the pyruvate 
kinase assay [14]. The purity of the cell prepara- 
tion is furthermore illustrated by the described 
selective increase of radioactivity in parenchymal 
cell preparations after estrogen treatment. 
2.3. Other determinations 
Protein determination was done as in [IS]. Liver 
wet weight for the studied rats is 3.75% of the 
body weight [16] and as the protein concentration 
in both parenchymal and non-parenchymal cells is 
identical (in mg/ml cell volume) [17], the relative 
protein contribution of parenchymal and non- 
parenchymal cells to total liver will be 92.5% and 
7.5%, respectively [16,18]. These calculations bas- 
ed upon morphometric data are further sustained 
by our earlier studies on enzyme distribution bet- 
ween the different cell types [19]. 
3. RESULTS 
The isolation of parenchymal and non- 
parenchymal cells was performed at a low 
temperature to prevent degradation of lipoproteins 
during the isolation procedure. 
A comparison of the low temperature procedure 
with the method exerted at 37°C [20] indicates that 
the recovery of radioactivity in the isolated cells, as 
compared to total liver, is quantitative for the cells 
isolated at low temperature (table 1). The increase 
in recovery from 39 to 105% is caused by a 2-fold 
higher amount of radioactivity recovered in paren- 
chymal cells and a 4-fold higher value in non- 
parenchymal cells leading to a doubling of the 
ratio of specific radioactivity of non-parenchymal 
over parenchymal cells. 
In ethinyl estradiol-treated rats the disap- 
pearance rate of human LDL from the plasma is 
markedly increased as compared to untreated rats 
(fig.1) while the uptake of human LDL in the liver 
is 5-fold higher (table 2). The removal from serum 
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Table 1 
Distribution of human 1311-LDL between parenchymal 
and non-parenchymal liver cells, isolated at low (8°C) 
and high (37”C)* temperature 30 min after intravenous 
injection 
070 x 104 of the injected dose/ 
mg cell proteinb 
Whole rat liver 
Parenchymal cells 
8°C method 37°C method* 
15.0 f 1.2 (6) 14 f 1 
(PC) 5.8 f 1.3 (3) 3*0 
Non-parenchymal 
cells (NPC) 138.3 f 6.8 (3) 
Ratio NPC/PC 23.8 
Recovery (vo)’ 105.3 f 3.3 (3) 
* Values obtained from [20] 
b Mean f SE, n in parentheses 
33 f 6 
11 
39 f 4 
c The mean recovery of the radioactivity in the cells 
isolated by the 8°C method as compared to whole liver 
with inclusion of estradiol-treated rats and Me-LDL is 
104.5 f 3.6% (n = 10) 
1 
and uptake in liver of human Me-LDL is not in- 
fluenced by estradiol treatment. For human LDL 
and human Me-LDL the radioactivity in plasma is 
for 98.3% and 99.4% trichloroacetic acid- 
precipitable, respectively. This percentage remains 
constant during the 30 min of circulation both for 
control and estradiol-treated rats. 
Fig. 1. Removal from blood plasma of human 1311-LDL 
and reductive methylated human 1251-LDL in control 
and 17a-ethinyl estradiol-treated rats. Human 1311-LDL 
( q , n ) and reductive methylated human 1251-LDL (0,o) 
were injected intravenously in control (open symbols) 
and estradiol-treated rats (closed symbols). 
Radioactivity was determined in50 ~1 samples of serum. 
Each point f SE represents he mean value from 6 rats. 
Estradiol-treatment of rats leads to a 13-fold 
higher amount of human LDL associated with 
parenchymal cells, while no effect is seen on the 
association with non-parenchymal cells (table 3). 
For the human Me-LDL there is only a slight incre- 
ment in the parenchymal cell-associated radioac- 
tivity. The difference in the amount of cell- 
association of native LDL and reductive 
methylated LDL can be considered to represent he 
receptor-mediated uptake [6]. This receptor- 
dependent uptake is clearly present in both paren- 
chymal and non-parenchymal cells from untreated 
rats and increased 17-fold in parenchymal cells 
from estradiol-treated rats, while there is no 
significant effect of estradiol-treatment on the 
non-parenchymal cell uptake. The increased up- 
take of human LDL by parenchymal cells is not 
simply caused by the reduced mass of native rat 
LDL in ethinyl estradiol-treated rats, because the 
simultaneous injection of a lo-fold excess of 
human LDL did not change the relative uptake in 
control and estradiol-treated rats (table 4). 
Taking into account the relative protein con- 
tribution of parenchymal and non-parenchymal 
Effect of estradiol treatment on the liver uptake of 
human 13’1-LDL and human Me-1251-LDL 30 min after 
intravenous injection 
% of the injected osea 
Human LDL Human 
Me-LDL 
Untreated 2.8 f 0.2 (6) 1.0 f 0.1 (7) 
Estradiol-treated 13.5 f 1.2 (7) 1.0 f 0.0 (8) 
a Mean f SE, n in parentheses 
April 1983 
0 5 10 15 20 25 
minutes after injection 
Table 2 
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Table 3 
distribution of human ‘3’I-LDL and human Me- ‘%LDL between p~en~hymai and nou-paren~hymal ceIIs in control 
and 17cu-ethinyl estradioi-treated rats 30 mink after intravenous injection 
% x lO‘$ of the injected dose/mg cell protein* 
Human LDL Human Me-LDL Receptor-dependentb 
cell association 
Whole Iiver 
untreated 15.0 f 1.2 (6) 5.8 f 0.5 (6) 9.3 f 1.0 (6) 
estradiol-treated 82.2 I 5.4 (6) 5.9 f 0.2 (6) 75.4 -1- 5.4 (6) 
Parenchymal cells 
untreated 5.8 k 1.3 (4) 1.5 zfz 0.1 (3) 4.3 3- 1.2 (3) 
e&radio&treated 78.0 -+ 3.7 (4) 2.7 * 0.1 (4) 75*0 + 3.7 (4) 
Non-parenchymal cells 
untreated 138.3 f 6.8 (3) 67.4 f 8.0 (3) 70.9 f 8.7 (3) 
estradiol-treated 126.7 f 13.3 (3) 40.9 f 6.8 (3) 85.9 f 6.8 (3) 
a Mean + SE, II in parentheses 
’ R~eptor~e~ndent ceI1 association is the difference between human “‘I-LDL and human Me-“‘1-LDL 
cells to total liver it can be calculated that in the treated rats the non-parenchymal cells ‘are quan- 
estrogen-treated rats, the parenchymal cells form titatively more important with 57% of the total 
the major tissue site for receptor-dependent liver receptor-dependent cell-association for human 
uptake of human LDL (929’0). In contrast, in un- LDL. 
Table 4 
Effect of a lo-fold excess of unlabeled human-LDL on 
the uptake of human “‘I-LDL and human Me-‘%LDL 
in parenchymal ceIIs of untreated and 1%“ethingl 
estradiol-treated rats, 30 min after intravenous 
injections 
4. DISCUSSION 
% x Iti of the injected dose 
/mg cell proteinb 
Human LDL Human 
Me-LDL 
Whole liver 
untreated 16.5 1 0.8 8.9 + 1.6 
estradiol-treated 86.1 + 15.2 13.5 * 3.9 
Parenchymal cells 
untreated 8.1 * 0.2 3.9 & 0.2 
~tra~ol-treated 102.9 + l-4 8.0 f 4.4 
a Containing: (1st expt) 34pg human “‘I-LDL, 19pg 
human Me-“251-LDL and 335 fig unlabeled human 
LDL; (2nd expt) 51 pg human ‘“‘I-LDL, 19 pg human 
Me-‘%LDL and 67Opg unlabeled human LDL 
bMean*tE,n=2 
The cellular localization of the liver uptake of 
human LDL in vivo could be determined quan- 
tit~~vely by taking 2 precautions to prevent loss of 
lipoprotein degradation products from the cells. 
(1) A circulation time of 30 min was chosen. In 
this time interval no increase af trichloroacetic 
acid-soluble products in serum occurs, nor is 
there any difference in the amount of the acid- 
soluble products between treated and control 
rats. A similar lag phase for human LDL 
degradation in rats is found in [Z]. 
(2) A cell isolation procedure for parenchymal 
and non-parenchymal cells was performed in 
which no loss of degradation products occurs. 
This was achieved by maintaining a low 
temperature during the initial liver perfusion 
and subsequent isolation of the liver cells. The 
data indicate that this procedure leads to a 
quantitative recovery of the total liver- 
associated radioactivity in the subsequently 
isolated cells. 
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The simultaneous circulation of native and Me- 
LDL enables us to discriminate between receptor- 
dependent and receptor-independent uptake. [6]. 
By applying a sucrose-label [27] in total liver 
67.4% of the total LDL uptake was shown to be 
receptor-mediated. For whole rat liver we obtain a 
value of 61.3%. The present results indicate that in 
normal rats both in parenchymal and non- 
parenchymal cells a receptor-mediated uptake 
mechanism for human LDL is present. These data 
obtained in vivo, confirm data obtained in vitro, 
which showed the presence of a human LDL recep- 
tor in freshly isolated parenchymal cells [9] and 
non-parenchymal cells [21] from untreated rats. 
Estradiol treatment of the rats selectively increases 
the receptor-mediated uptake of human LDL in 
parenchymal cells, while the uptake in non- 
parenchymal cells is not affected. The paren- 
chymal liver cells are therefore solely responsible 
for the increased liver-association of human LDL 
in estradiol-treated rats and form then the major 
liver site for receptor-dependent cell-association of 
human LDL with 92% of the total liver amount. 
This value agrees with autoradiographic data [5], 
which indicated that 5-15% of the grains of 
radiolabeled human LDL were seen over non- 
parenchymal cells after estrogen-treatment. In un- 
treated rats, however, the non-parenchymal cells 
are quantitatively an important liver site for 
receptor-dependent cell-association of human 
LDL with 57% of the total liver uptake. The 
receptor-independent uptake of human LDL in rat 
liver is not influenced by estrogen-treatment and is 
mainly exerted by the non-parenchymal cells. 
The properties of the estradiol-stimulated 
lipoprotein receptor of rat liver are extensively 
described in [2-41 and it appears that it reflects the 
LDL receptor characterized on extrahepatic cells 
(review [22]). However, in these studies membrane 
preparations from total liver or liver perfusions are 
used and it was not possible to decide if the 
estradiol-induced LDL binding sites and the 
enhanced LDL uptake occurs in parenchymal or 
non-parenchymal cells [3]. Our data indicate that 
selectively parenchymal cells show an increased up- 
take of human LDL as a result of estrogen- 
treatment and consequently the metabolism of 
LDL inside the liver is not only quantitatively but 
also in relation to cellular sites greatly changed. 
With parenchymal iver cells isolated from un- 
treated rats, we investigated the properties of a 
binding site for human LDL [9]. It was found that 
human LDL is bound with high affinity and the 
binding site recognizes both apo B as well as apo 
E containing lipoproteins and resembles the in- 
ducible apo B,E receptor [23]. These properties 
differ from the receptor which mediates the uptake 
of rat very low density lipoprotein (VLDL)- 
remnants 1241 or rat chylomicron-remnants 
[25,26]. This remnant receptor, recognizing apo E, 
does not interact with human LDL. The ability to 
induce selectively the apo B,E receptor in paren- 
chymal liver cells and not in non-parenchymal cells 
may form an important tool to determine the 
relative importance of the different cell types and 
receptors for liver lipoprotein metabolism. 
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